FDA-approved1,2Evidence: Large human trialsHormones · Brain, nerves and sleep

Oxytocin1

Also called Pitocin1,2

Key takeaway

Oxytocin is a nine-amino-acid peptide hormone found in the pituitary gland. A synthetic version is the active ingredient in Pitocin.1,2 Its U.S. label covers starting or strengthening labor contractions when there is a medical reason, and controlling bleeding after birth. The label states that it is not indicated for elective induction of labor.1 In a randomized trial of 29,645 participants published in 2018, oxytocin and heat-stable carbetocin, a related drug, prevented heavy bleeding after vaginal birth about equally often.3

Oxytocin at a glance

What it isA synthetic version of oxytocin, a nine-amino-acid hormone found in the pituitary gland, according to the Pitocin label.1
FDA statusFDA-approved. Drugs@FDA lists Pitocin, NDA 018261, with an original approval date of November 19, 1980. The label’s boxed warning states that it is not indicated for elective induction of labor.1,2
Human evidenceDecades of clinical use described in the label, which does not report its own trials, and large randomized trials published in journals, including one of 29,645 participants.1,3
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is oxytocin?

Oxytocin is a peptide hormone of nine amino acids found in pituitary extracts from mammals. The version in Pitocin is made synthetically, which the label says avoids possible contamination with vasopressin.1

In the United States it is the active ingredient of Pitocin, approved under NDA 018261, according to Drugs@FDA.2

How does oxytocin work?

The label states that oxytocin promotes contractions of the uterus by raising calcium inside its muscle cells, acting on oxytocin receptors whose number rises greatly during pregnancy.1

The label also states that oxytocin has some antidiuretic and blood-pressure effects, because it differs from vasopressin in only two of its amino acids.1

What do human studies show?

The Pitocin label describes how oxytocin acts and its risks, but does not report clinical trials of its own.1

ClinicalTrials.gov lists completed Phase 4 trials of oxytocin in bleeding after birth caused by a slack uterus (NCT00790062) and in strengthening labor (NCT00906347).4,5

Registered trials also study oxytocin outside its labeled uses. ClinicalTrials.gov lists completed Phase 2 studies in postpartum depression and anxiety (NCT02505984) and in autism spectrum disorder (NCT02918864); the registry records cited here do not report their findings.6,7

CHAMPION, a randomized, double-blind trial of 29,645 participants in 10 countries published in 2018, compared oxytocin with heat-stable carbetocin given right after vaginal birth. Blood loss of at least half a litre, or the need for more drugs to contract the uterus, occurred in 14.4% of those given oxytocin and 14.5% of those given carbetocin.3

What the evidence base contains

  • Large randomized human trial CHAMPION: a randomized, double-blind trial of 29,645 participants giving birth vaginally in 10 countries, comparing heat-stable carbetocin with oxytocin for preventing bleeding after birth (2018).3

Evidence-strength label: Large randomized human trials. How this label is assigned

Is oxytocin FDA-approved?

Yes. Drugs@FDA lists Pitocin, application NDA 018261, with an original approval date of November 19, 1980.2

The Pitocin label cited here (DailyMed SPL version 15, published May 21, 2026) states that it is indicated to start or improve contractions when there is a medical reason to deliver, to reinforce labor in selected cases, as an added treatment in incomplete or inevitable abortion, and after birth to control bleeding.1

The label carries a boxed warning, headed “Important notice”, stating that Pitocin is not indicated for elective induction of labor because the available data are inadequate to weigh its benefits and risks for that use.1

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Oxytocin is not among them.8,9

Timeline

  1. FDA approves the Pitocin application cited here, NDA 018261, according to Drugs@FDA.2
  2. The CHAMPION trial comparing heat-stable carbetocin with oxytocin in 29,645 participants is published.3
  3. DailyMed publishes the Pitocin label version cited on this page.1

What is still unknown?

Whether its benefits outweigh its risks for elective induction of labor, which the label states the available data are inadequate to judge.1

Whether oxytocin helps in conditions outside pregnancy and birth, such as postpartum depression or autism: registered trials have studied these, but the registry records cited here do not report results.6,7

Whether carbetocin prevents the heaviest bleeding as well as oxytocin: in CHAMPION, the result for blood loss of at least one litre did not show that, partly because such bleeding was rare.3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Oxytocin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Oxytocin are a bounded selection, not every registration or paper about Oxytocin. For the years before Oxytocin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Oxytocin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Oxytocin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Pitocin for labor and bleeding after birth. The label does not report its own trials. A randomized trial of 29,645 participants found oxytocin and heat-stable carbetocin similar for preventing bleeding after vaginal birth. The label states that Pitocin is not indicated for elective induction of labor.↗↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Oxytocin?

FDA-approved as Pitocin for labor and bleeding after birth. The label does not report its own trials. A randomized trial of 29,645 participants found oxytocin and heat-stable carbetocin similar for preventing bleeding after vaginal birth. The label states that Pitocin is not indicated for elective induction of labor.↗↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
24
Drugs@FDA applications
8

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date November 16, 2026

ClinicalTrials.gov record NCT06285396↗Added to PeptideScanner November 16, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Oxytocin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

82Selected dated records
87Connected citations
24Populated source years1980–2026
3/4Record lanes present

Registered human studies

Trial composition

27 of 27 selected trial records include at least one phase value; 27 of 27 include a status value in the retained structured contract.

PhasesPhase 4 16Phase 2 7Phase 3 3Not applicable 2
Status at observationCompleted 25Active, not recruiting 1Recruiting 1

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 25Review 20Research Support, Non-U.S. Gov't 5Randomized Controlled Trial 3Systematic Review 2English Abstract 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
8
FDA Federal Register documents
22
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
82

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 82 dated records

Research hub

Explore the Oxytocin evidence record

Open all 82 records →
82Dated records
3Evidence types
82Cited public sources
24Source years

Change ledger

Recently changed for Oxytocin

Open all 82 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00790062

PeptideScanner retained ClinicalTrials.gov record NCT00790062 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-04-08, and PeptideScanner's reviewed identity mapping was oxytocin.

PeptideScanner change date
November 16, 2026
Cited source date
April 8, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00906347

PeptideScanner retained ClinicalTrials.gov record NCT00906347 at 2026-11-16T00:59:19.138Z. Its registry update date was 2012-11-15, and PeptideScanner's reviewed identity mapping was oxytocin.

PeptideScanner change date
November 16, 2026
Cited source date
November 15, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00919802

PeptideScanner retained ClinicalTrials.gov record NCT00919802 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-05-23, and PeptideScanner's reviewed identity mapping was oxytocin.

PeptideScanner change date
November 16, 2026
Cited source date
May 23, 2017
Evidence lane
Clinical trials

Official-source collections

Source records for Oxytocin

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. Context-dependent oxytocin receptor signaling: from molecular architecture to transcript-level receptor engineering.Frontiers in neuroscience · 2026 10 06
  2. Opioids and the oxytocin system: Mechanistic interactions altering maternal neuroplasticity.Journal of neuroendocrinology · 2026 Oct
  3. Endometrial Preparation Strategies for Frozen Embryo Transfer in Women with Adenomyosis: A Systematic Review of Hormone Replacement Therapy, Gonadotropin-Releasing Hormone Agonist, and Oxytocin Antag…International journal of women's health · 2026 09 21
Explore all selected literature →
ClinicalTrials.gov27

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06285396Registry update November 16, 2026 · current at observation
  2. NCT06930391Registry update November 13, 2026 · current at observation
  3. NCT04228289Registry update March 11, 2026 · completed at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA8

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA091676Full FDA chronology · original submission status AP 2018-07-13
  2. ANDA200219Full FDA chronology · original submission status AP 2013-02-13
  3. ANDA077453Full FDA chronology · original submission status AP 2008-01-24
  4. NDA019185Full FDA chronology · original submission status AP 1985-03-29
  5. NDA018261Full FDA chronology · original submission status AP 1980-11-19
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Oxytocin →

Evidence types

Coverage by source year

Selected records span April 17, 1980 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
  • U.S. Department of Health and Human Services8
Dated updates connected to this profile · 82

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT06285396↗

    PeptideScanner retained ClinicalTrials.gov record NCT06285396 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was oxytocin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT06930391↗

    PeptideScanner retained ClinicalTrials.gov record NCT06930391 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was oxytocin.↗

  3. Literature metadata

    Oxytocin and social neuroscience - sexually dimorphic OXTR neurons in mouse preoptic area.↗

    PubMed lists PMID 42191115 in Progress in neurobiology as Journal Article, Review, with publication-date metadata of 2026-05-25 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Oxytocin and autism - A precision medicine framework to unpack mechanisms and evidence.↗

    PubMed lists PMID 42144048 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Beyond lactation: Central oxytocin in maternal mental health and disease.↗

    PubMed lists PMID 42002246 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Oxytocin, sex hormones and brain activity in facial expression processing: A sex-based systematic review.↗

    PubMed lists PMID 41707759 in Neuroscience and biobehavioral reviews as Journal Article, Systematic Review, with publication-date metadata of 2026-02-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Rewiring connection: The role of oxytocin in interactive media behavior.↗

    PubMed lists PMID 41796877 in Neuroscience and biobehavioral reviews as Journal Article, Review, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Reframing oxytocin as a behavioral flexibility hormone.↗

    PubMed lists PMID 41796879 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    A narrative review on oxytocin at the intersection of sleep, stress, and social behavior.↗

    PubMed lists PMID 42093825 in Frontiers in neuroscience as Journal Article, Review, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Role of Oxytocin in Obesity.↗

    PubMed lists PMID 42766066 in Current diabetes reports as Journal Article, Review, with publication-date metadata of 2026-09-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Oxytocin in chronic pain: From analgesic to biopsychosocial adjuvant - An opinion paper.↗

    PubMed lists PMID 41619996 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-01-29 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Opioids and the oxytocin system: Mechanistic interactions altering maternal neuroplasticity.↗

    PubMed lists PMID 42876328 in Journal of neuroendocrinology as Journal Article, Review, with publication-date metadata of 2026-10 (month precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    PITOCIN (oxytocin) injection · SPL version 15 · published 2026-05-21 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: PITOCIN (oxytocin), NDA 018261 · original approval November 19, 1980 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth (2018) · PMID 29949473 ↗

    The New England Journal of Medicine · Official source · Source checked November 15, 2026

  4. 4
    ClinicalTrials.gov record NCT00790062 · retained source version 2016-04-08:7fd85d675afea436a0e0ba315435702d4d25721b0bafbc3b162070b114b97cf9 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  5. 5
    ClinicalTrials.gov record NCT00906347 · retained source version 2012-11-15:a195f10f34551b96615567421134c58e7b9bc1c4159e599600084ce4155d41eb ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  6. 6
    ClinicalTrials.gov record NCT02505984 · retained source version 2025-02-25:ba2af36f94b77f220805b39c62fe306d0b89aed52b0abe0465542114e26d499c ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  7. 7
    ClinicalTrials.gov record NCT02918864 · retained source version 2024-04-05:65c3715794e007eafef745e7e331fc9d327005aeea2e4db502701c5514f4d6fe ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  8. 8
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026